Evidence map›Paper›PMID 18000649›Full record

ArticleIntensive care medicine2008

Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature.

G Umberto Meduri, Paul E Marik, George P Chrousos, Stephen M Pastores, Wiebke Arlt, Albertus Beishuizen, Faran Bokhari, Gary Zaloga, Djillali Annane

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
9.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Dexamethasone inhibits endotoxin-induced coagulopathy in human lungs.Journal of thrombosis and haemostasis : JTH · 2016
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Role of Glucocorticoids in the Management of COVID-19.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 5 countries.

G Umberto MeduriUniversity of Tennessee Health Science Center and Memphis VA Medical Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Room H316, 956 Court Avenue, TN 38163, Memphis, USA. umeduri@utmem.edu
Paul E Marik
George P Chrousos
Stephen M Pastores
Wiebke Arlt
Albertus Beishuizen
Faran Bokhari
Gary Zaloga
Djillali Annane
Amsterdam UMC Location VUmc · NLAthens Medical Center · GRBaxter (United States) · USJohn H. Stroger, Jr. Hospital of Cook County · USMemorial Sloan Kettering Cancer Center · USMemphis VA Medical Center · USThomas Jefferson University · USUniversité de Versailles Saint-Quentin-en-Yvelines · FRUniversity of Birmingham · GB

Funding

Medical Research Council G116/172
6 · The paper itself

Abstract

objectivesTo compare the design and results of randomized trials investigating prolonged glucocorticoid treatment (> or =7 days) in patients with acute lung injury-acute respiratory distress syndrome (ALI-ARDS), and review factors affecting response to therapy, including the role of secondary prevention.

designTrials were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL). Two investigators collected data on study characteristics, treatment intervention, and outcomes. The methodological quality of trials was determined and data were analyzed with Review Manager 4.2.3. MEASUREMENTS AND

resultsFive selected trials (n=518) consistently reported significant improvement in gas exchange, reduction in markers of inflammation, and decreased duration of mechanical ventilation and intensive care unit stay (all p<0.05). Two early small clinical trials showed marked reductions in the relative risk (RR) of death with glucocorticoid therapy (RR=0.14, 95% CI 0.04-0.53; p=0.004, I2=0%). Three subsequent larger trials, when combined, although nominally beneficial, did not reproduce the marked reductions observed in the earlier trials (RR=0.84; 95% CI 0.68-1.03; p=0.09, I2=9.1%), but achieved a distinct reduction in the RR of death in the larger subgroup of patients (n=400) treated before day 14 of ARDS [82/214 (38%) vs. 98/186 (52.5%), RR=0.78; 95% CI 0.64-0.96; p=0.02, I2=0%].

conclusionsProlonged glucocorticoid treatment substantially and significantly improves meaningful patient-centered outcome variables, and has a distinct survival benefit when initiated before day 14 of ARDS.

Indexed as

Randomized Controlled Trials as TopicFemaleGlucocorticoidsHumansMaleProcollagenRegistriesRespiratory Distress SyndromeTreatment OutcomeGlucocorticoidsProcollagen

Identifiers

PMID18000649
OpenAlexW2148644648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.